Assessment of Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy.

ABSTRACT:

Importance

There are few studies assessing the association of tumor mutational burden (TMB) and clinical outcomes in a large cohort of patients with diverse advanced cancers.

Objective

To clinically validate a TMB biomarker from a next-generation sequencing targeted gene panel assay.

Design, setting, and participants

A prespecified cohort study using the deidentified clinicogenomic Tempus database of patients sequenced between 2018 and 2022, which contained retrospective, observational data originating from 300 cancer sites including 199 community sites and 101 academic sites. Patients with advanced solid tumors across 8 cancer types and more than 20 histologies, sequenced with Tempus xT who were treated with immune checkpoint inhibitors (ICIs) in the first-line or se

SUBMITTER: Aggarwal C 

PROVIDER: S-EPMC10155064 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature